32.Issue 01 january 22 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 09, Issue : 01, January – 2022

Title:

32.REVIEW ON OMICRON: A NEW EMERGING STRAIN OF COVID-19

Authors :

Sumit S. Bodkhe, Ashok A. Muchandi, Ashwini G. Chintale

Abstract :

COVID-19 has brought about a worldwide threat to the public health. Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.529 has been found in South Africa and it leads to rapid increase in COVID-19 cases. On November 24, 2021, B.1.1.529 named Omicron was identified as a variant under monitoring (VUM) by World Health Organization. Two days later, the Omicron variant was categorised as a variant of concern (VOC). This variant harbour a large number of mutations, including 15 mutations in the receptor-binding domain (RBD) of spike. The Omicron variant of COVID-19 also shares variety of mutations with the previous VOC Alpha, Beta, and Gamma variants, which quickly raised global concerns about viral pathogenicity, transmissibility, and immune evasion. Here we described the discovery and characteristics of the Omicron variant, Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection, and further raised possible remedies to prevent and combat the prevalence of the Omicron variant.

Cite This Article:

Please cite this article in press Sumit S Bodkhe et al, Review on Omicron: A New Emerging Strain Of Covid-19., Indo Am. J. P. Sci, 2022; 09(01).

Number of Downloads : 10

References:

1. WHO. WHO Coronavirus disease (COVID-19) pandemic. 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
2. WHO. Tracking SARS-CoV-2 variants. 2021. https://www. who.int/en/activities/tracking-SARS-CoV-2-variants.
3. WHO. Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member states. https://www.who.int/docs/default-source/coronaviruse/technical-brief-and-priority-action-on omicron.pdf?sfvrsn= 50732953_3.
4. Graham F. Daily briefing: omicron coronavirus variant puts scientists on alert. Nature.
5. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10317):2126-2128.
6. WHO. South Africa. 2021. https://covid19.who.int/region/afro/ country/za.
7. CBS NEWS. Omicron COVID variant was in Europe before South African scientists detected and flagged it to the world. 2021. https://www.cbsnews.com/news/omicron-variant-covid-in-europe-netherlands-before-alert-raised/
8. WHO. B.1.1.529. 2021. https://cov-lineages.org/global_report_B. 1.1.529.html.
9. GISAID. Covariants. 2021. https://covariants.org/variants/21K. Omicron. Accessed December 7, 2021.
10. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215-220.
11. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-1448.
12. Yuan M, Liu H, Wu NC, Wilson IA. Recognition of the SARSCoV- 2 receptor binding domain by neutralizing antibodies. Biochem Biophys Res Commun. 2021;538:192-203.
13. Zimerman RA, Gröhs Ferrareze PA, Cadegiani FA, et al. Comparative genomics and characterization of SARS-CoV-2 P.1 (Gamma) variant of concern (VOC) from Amazonas, Brazil. medRxiv. Published onlineNovember 1, 2021. https://doi.org/10. 1101/2021.10.30.21265694.
14. Starr TN, Greaney AJ, Dingens AS, Bloom JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody
15. Wuhanupdate. Coronavirus outbreak breaking news. Pfizer shot provides partial omicron shield in early study (2). 2021. https://www.wuhanupdate.com/politics/pfizer-shot-providespartial- omicron-shield-in-early-study-2-64686804.
16. Cele S, Jackson L, Khan K, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv. 2021.
17. He C, Yang J,He X, et al. A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus. MedComm. 2021;2(3):430-441.
18. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021;27(11):2025-2031.
19. BioSpace. Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day. 2021. https://www.biospace.com/article/releases/modernaannounces- significant-advances-across-industry-leadingmrna- portfolio-at-2021-r-and-amp-d-day/